Table 2. Transmitted drug resistants (TDRs) at baseline (n = 80).
| Total | Subtype B (n = 64) | Non-B (n = 7) | Unknown (n = 9) | |
|---|---|---|---|---|
| NRTI TDR (n, %) | ||||
| M41L* | 26 (32.5) | 25 (39.1) | 1 (14.3) | 0 (0) |
| K65R | 3 (3.8) | 2 (3.1) | 1 (14.3) | 0 (0) |
| D67N/G/E | 18 (22.5) | 16 (25.0) | 2 (28.6) | 0 (0) |
| T69D | 11 (13.8) | 10 (15.6) | 1 (14.3) | 0 (0) |
| K70R/E | 17 (21.3) | 15 (23.4) | 2 (28.6) | 0 (0) |
| L74V/I | 5 (6.3) | 5 (7.8) | 0 (0) | 0 (0) |
| F77L | 3 (3.8) | 3 (4.7) | 0 (0) | 0 (0) |
| F116Y | 2 (2.5) | 2 (3.1) | 0 (0) | 0 (0) |
| Q151M | 3 (3.8) | 3 (4.7) | 0 (0) | 0 (0) |
| M184V/I | 36 (45.0) | 27 (42.2) | 6 (85.7) | 3 (33.3) |
| L210W | 22 (27.5) | 21 (32.8) | 0 (0) | 1 (11.1) |
| T215Y/F/I/S* | 33 (41.3) | 31 (48.4) | 2 (28.6) | 0 (0) |
| K219Q/E/N/R | 21 (26.3) | 19 (29.7) | 2 (28.6) | 0 (0) |
| NNRTI TDR (n, %) | ||||
| K101E | 8 (10.0) | 8 (12.5) | 0 (0) | 0 (0) |
| K103N/S* | 28 (35.0) | 27 (42.2) | 1 (14.3) | 0 (0) |
| V106M/A | 4 (5.0) | 4 (6.3) | 0 (0) | 0 (0) |
| Y181C/I/V | 36 (45.0) | 29 (45.3) | 5 (71.4) | 2 (22.2) |
| Y188C | 2 (2.5) | 2 (3.1) | 0 (0) | 0 (0) |
| G190A/S/E | 22 (27.5) | 17 (26.6) | 4 (57.1) | 1 (11.1) |
| P225H | 2 (2.5) | 2 (3.1) | 0 (0) | 0 (0) |
| PI TDR (n, %) | ||||
| V32I | 1 (1.3) | 1 (1.6) | 0 (0) | 0 (0) |
| V82F | 2 (2.5) | 1 (1.6) | 1 (14.3) | 0 (0) |
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TDR, transmitted drug resistant.
*, p<0.05